# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Beta Thalassemia

Beta-ThalassemiaThalassemia Major
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 44 results.
Dermatological Abnormalities in Beta-thalassemia Major
Status: Not yet recruiting
Last Changed: Mar 28, 2019
First Received: Mar 28, 2019
Disease(s): Beta-Thalassemia
Intervention(s): thalassemia
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
Status: Not yet recruiting
Last Changed: Nov 30, 2017
First Received: Nov 24, 2017
Disease(s): Beta-Thalassemia
Intervention(s): Gene-modified autologous stem cells
Locations: Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Detection Of β-thalassemia Carriers In Assiut
Status: Not yet recruiting
Last Changed: Jan 30, 2019
First Received: Jan 30, 2019
Disease(s): Beta-Thalassemia
Intervention(s): CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study
Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients
Status: Recruiting
Last Changed: Jul 02, 2019
First Received: Mar 18, 2019
Disease(s): Beta-Thalassemia
Intervention(s): Sirolimus 0.5 mg
Locations: Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, Ferrara, Italy
Department of Growth and Reproduction Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy
Apotransferrin in Patients With β-thalassemia
Status: Recruiting
Last Changed: Jun 20, 2019
First Received: Jun 20, 2019
Disease(s): β-thalassemia Intermedia
Intervention(s): human apotransferrin
Locations: Academic Medical Centre, Amsterdam-Zuidoost, Noord-Holland, Netherlands
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype
Status: Recruiting
Last Changed: Jan 31, 2019
First Received: Jul 02, 2017
Disease(s): Beta-Thalassemia
Intervention(s): LentiGlobin BB305 Drug Product
Locations: UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Hopital d'enfants de la Timone, Marseille, France
Hannover Medical School, Hannover, Germany
... and 5 other locations.
Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL)
Status: Recruiting
Last Changed: Apr 22, 2019
First Received: Sep 07, 2017
Disease(s): Beta Thalassaemia
Intervention(s): Safety and Efficacy assessments
Locations: Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET), Milan, Italy
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
Status: Recruiting
Last Changed: Jan 31, 2019
First Received: Sep 20, 2016
Disease(s): Beta-Thalassemia
Intervention(s): LentiGlobin BB305 Drug Product
Locations: Oakland, California, United States
Chicago, Illinois, United States
Philadelphia, Pennsylvania, United States
Marseille, France
Hannover, Germany
... and 5 other locations.
Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified
Status: Not yet recruiting
Last Changed: Sep 08, 2017
First Received: Sep 08, 2017
Disease(s): Beta Thalassemia Major
Intervention(s): Autologous CD34+ cells genetically modified
Locations: Nanfang Hospial, Guangzhou, Guangdong, China
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia
Status: Recruiting
Last Changed: Jan 10, 2019
First Received: Dec 22, 2017
Disease(s): Beta-Thalassemia
Intervention(s): LJPC-401, LJPC-401
Locations: Investigative Site, Los Angeles, California, United States
Investigative Site, Oakland, California, United States
Investigational Site, San Diego, California, United States
Investigative Site, Chicago, Illinois, United States
Investigative Site, New Hyde Park, New York, United States
... and 27 other locations.